Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017
After a horrible 2016 following the loss of its lead drug candidate, Alnylam Pharmaceuticals (NASDAQ: ALNY) has had a pretty stellar year, up 238% so far.
Much of that increase has come in the last few months after Alnylam and its partner, Sanofi (NYSE: SNY), announced that Alnylam's new lead drug, patisiran, which treats hereditary ATTR amyloidosis (hATTR), passed the phase 3 Apollo trial. A few months later, the companies presented details of the trial at a medical meeting, demonstrating how much the drug helped patients compared to placebo.
Source: Fool.com
Alnylam Pharmace. Aktie
216,20 €
-0,82 %
Uneingeschränkte Unterstützung für Alnylam Pharmace., ausschließlich Buy-Einschätzungen.
Ein leicht positives Potenzial wird für Alnylam Pharmace. mit einem Kursziel von 251 € im Vergleich zu 216.2 € gesehen.
